|
19 Oct 2023 |
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
|
|
19 Oct 2023 |
NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023
|
|
19 Oct 2023 |
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
|
|
19 Oct 2023 |
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
|
|
18 Oct 2023 |
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
|
|
11 Oct 2023 |
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma
|
|
11 Oct 2023 |
The SparX Group Enters into a Collaboration with Arovella Therapeutics for the Development of CLDN18.2-CAR-iNKT Cell Therapy
|
|
11 Oct 2023 |
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
|
|
11 Oct 2023 |
Myrtelle Announces Presentation of Positive 12-month Post Treatment Data in its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy at the 2023 Cell & Gene Meeting on the Mesa held by the Alliance for Regenerative Medicine
|
|
10 Oct 2023 |
Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy
|
|
08 Oct 2023 |
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
|
|
08 Oct 2023 |
Locanabio Announces Presentation of Preclinical Data Demonstrating an Improved Vectorized snRNA Platform with Applications in Exon Skipping for the Potential Treatment of Duchenne Muscular Dystrophy (DMD) at the 28th Annual Congress of the World Muscle So
|
|
05 Oct 2023 |
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
|
|
05 Oct 2023 |
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
|
|
05 Oct 2023 |
Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
|
|
04 Oct 2023 |
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
|
|
04 Oct 2023 |
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
|
|
04 Oct 2023 |
SOLA Biosciences Shares Preclinical Proof-of-Concept Data for SOL-257, a Gene Therapy Targeting Misfolded TDP-43 in ALS at 22nd Annual NEALS Meeting
|
|
04 Oct 2023 |
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
|
|
02 Oct 2023 |
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
|
|
02 Oct 2023 |
Nexcella Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
|
|
29 Sep 2023 |
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
|
|
29 Sep 2023 |
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
|
|
28 Sep 2023 |
Landmark Phase 3 MARIPOSA Study Meets Primary Endpoint Resulting in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival for RYBREVANT® (amivantamab-vmjw) plus Lazertinib Versus Osimertinib in Patients with EGFR-Mut
|
|
28 Sep 2023 |
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
|
